Business Wire

Cash Is King: Treasury Values Surge to $418B in Q1 According to Citco

11.5.2023 11:25:00 EEST | Business Wire | Press release

Share

The value of treasury transactions among alternatives and institutional funds increased by 25% to $418B in Q1 of this year from the previous quarter, according to the Citco group of companies (Citco), amid an on-going, near-unrecognizable interest rate environment and a surge in banking sector volatility.

The banking sector volatility seen in the first quarter – which resulted in the back-to-back collapses of Silicon Valley Bank and Signature Bank, as well as the takeover of Credit Suisse – created large cash movements and drove up the dollar value of funds. However, this flight did not entirely underpin this quarterly increase in transaction value: it is a continuation of last year’s trend of managers putting more cash to work as return-generating assets following soaring inflation and rapid rate hikes - as well as funding and transfers, the majority collateral-related resulting from increased margin calls.

According to Citco’s Q1 2023 Middle Office Solutions Report, the value of treasury transactions not only increased by 25% quarter-on-quarter, but the volume of securities-based margin movements also soared by 66% in Q1 - as managers looked to post securities rather than cash as collateral, leaving cash to work as an alpha-generating tool.

Cash margin is still relevant, but only increased by 10% in Q1 as securities took a larger portion, while we saw a slight increase of 14% in overall margin calls.

Ryan Fitzgerald, Head of Middle Office Solutions, Citco Fund Services (USA) Inc. said: “Given current high interest rates, it is clear that managers are now evaluating putting cash to work in higher interest rate products, while posting securities as collateral – another signifier that cash is now seen as an alpha-generating tool.

“For now, as always, the focus for managers’ Middle Office teams is how to reduce costs and increase operational efficiency. In addition, the materiality of margin costs have pushed Middle- and Back-Office concerns very much into the Front-Office mind-set. Therefore, demand for more treasury management shows no signs of abating. Managers are increasingly reviewing their operating systems and many are facing a choice - either invest in building the infrastructure to manage cash effectively and meet regulatory requirements, or outsource.”

Meanwhile, regulations continue to have an impact. New Central Securities Depositories Regulation (CSDR) rules in Europe have also led to a rise in EU managers seeking pre-settlement services; overall, Citco saw a 59% increase in the number of clients using Trade Matching services in 2022, and a further increase of 14% in Q1 2023 on the previous quarter.

The Middle Office Solutions Report contains data on overall trade volumes, values and collateral calls for Q1 2023.

Data on payments volumes and collateral moves are constituted by all dispatched payments including Letter of Acceptances. All data is drawn from clients using Citco’s proprietary systems, Æxeo® Collateral and Æxeo® Treasury. All transaction types are included from tax payments to loan funding, transaction costs, cash collateral and OTC settlements, among others. The underlying funds include all Hedge, Private Markets, Real Assets, Family Office and Institutional funds in our client base encompassing a significant proportion of Citco’s $1.8T in Assets Under Administration.

--ENDS--

Notes to Editors

About the Citco group of companies (Citco)

The Citco group of companies (Citco) is a network of independent companies worldwide. These companies are leading providers of asset-servicing solutions to the global alternative investment industry. With over $1.8 trillion in assets under administration and operations spanning across 36 countries, Citco’s unique culture of innovation and client-driven solutions have provided Citco’s clients with a trusted partner for more than four decades. Having grown organically into one of the largest asset servicers in the industry, Citco’s Fund Services companies offer a full suite of middle office and back office services including, treasury and loan handling, daily NAV calculations and investor services, corporate and legal services, regulatory and risk reporting as well as tax and financial reporting services. Investing heavily in innovation and technology whilst further developing its current suite of client-friendly solutions, Citco will continue into the future as a flagbearer for the asset-servicing industry.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
citco@instinctif.com
Victoria Hayns / Bryn Woodward / Vivian Lai at Instinctif Partners
+44 (0) 20 7457 2045 / +44 (0) 207 457 2040

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye